{"protocolSection": {"identificationModule": {"nctId": "NCT00403754", "orgStudyIdInfo": {"id": "CQAB149A1202"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Dose Ranging Study for Indacaterol in Japanese Asthma Patients", "officialTitle": "A Randomized, Double-blind, Placebo-controlled, 4-period 4-treatment Crossover, Multicenter, Single-dose, Dose-ranging Study Followed by a Single Day's Treatment With Open Label Salmeterol Bid (100 \u00b5g/Day), to Assess the Efficacy and Safety of 3 Doses of Indacaterol (150, 300, & 600 \u00b5g) Delivered Via Single Dose Dry Powder Inhaler (SDDPI) in Japanese Asthma Patients"}, "statusModule": {"statusVerifiedDate": "2011-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-11"}, "primaryCompletionDateStruct": {"date": "2007-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-11-23", "studyFirstSubmitQcDate": "2006-11-24", "studyFirstPostDateStruct": {"date": "2006-11-27", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-07-22", "resultsFirstSubmitQcDate": "2011-07-22", "resultsFirstPostDateStruct": {"date": "2011-08-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-07-22", "lastUpdatePostDateStruct": {"date": "2011-08-17", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study was designed to provide data about the safety and efficacy of 3 doses of indacaterol (150, 300, and 600 \u00b5g) in Japanese asthma patients so that an optimal dose, or doses, could be chosen for testing in later studies."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["asthma", "QAB149", "indacaterol", "long acting \u03b22-agonist", "bronchodilator"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 41, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo-Ind 150 \u03bcg-Ind 300 \u03bcg-Ind 600 \u03bcg-Salmeterol", "type": "EXPERIMENTAL", "description": "In treatment period 1: patients received 2 placebo capsules; in treatment period 2: patients received 1 indacaterol (Ind) 150 \u03bcg capsule + 1 placebo capsule; in treatment period 3: patients received 1 indacaterol 300 \u03bcg capsule + 1 placebo capsule; and in treatment period 4: patients received 2 indacaterol 300 \u03bcg capsules. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 \u03bcg salmeterol (50 \u03bcg in the morning, 50 \u03bcg twelve hours post initial dose) inhaled via Diskus\u00ae, an inhalation device, on Day 1.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol", "Drug: Placebo", "Drug: Salmeterol"]}, {"label": "Ind 150 \u03bcg-Ind 600 \u03bcg-Placebo-Ind 300 \u03bcg-Salmeterol", "type": "EXPERIMENTAL", "description": "In treatment period 1: patients received 1 indacaterol (Ind) 150 \u03bcg capsule + 1 placebo capsule; in treatment period 2: patients received 2 indacaterol 300 \u03bcg capsules; in treatment period 3: patients received 2 placebo capsules; and in treatment period 4: patients received 1 indacaterol 300 \u03bcg capsule + 1 placebo capsule. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 \u03bcg salmeterol (50 \u03bcg in the morning, 50 \u03bcg twelve hours post initial dose) inhaled via Diskus\u00ae, an inhalation device, on Day 1.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol", "Drug: Placebo", "Drug: Salmeterol"]}, {"label": "Ind 300 \u03bcg-Placebo-Ind 600 \u03bcg-Ind 150 \u03bcg-Salmeterol", "type": "EXPERIMENTAL", "description": "In treatment period 1: patients received 1 indacaterol (Ind) 300 \u03bcg capsule + 1 placebo capsule; in treatment period 2: patients received 2 placebo capsules; in treatment period 3: patients received 2 indacaterol 300 \u03bcg capsules; and in treatment period 4: patients received 1 indacaterol 150 \u03bcg capsule + 1 placebo capsule. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 \u03bcg salmeterol (50 \u03bcg in the morning, 50 \u03bcg twelve hours post initial dose) inhaled via Diskus\u00ae, an inhalation, device on Day 1.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol", "Drug: Placebo", "Drug: Salmeterol"]}, {"label": "Ind 600 \u03bcg-Ind 300 \u03bcg-Ind 150 \u03bcg-Placebo-Salmeterol", "type": "EXPERIMENTAL", "description": "In treatment period 1: patients received 2 indacaterol (Ind) 300 \u03bcg capsules; in treatment period 2: patients received 1 indacaterol 300 \u03bcg capsule + 1 placebo capsule; in treatment period 3: patients received 1 indacaterol 150 \u03bcg capsule + 1 placebo capsule; and in treatment period 4: patients received 2 placebo capsules. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 \u03bcg salmeterol (50 \u03bcg in the morning, 50 \u03bcg twelve hours post initial dose) inhaled via Diskus\u00ae, an inhalation device, on Day 1.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol", "Drug: Placebo", "Drug: Salmeterol"]}], "interventions": [{"type": "DRUG", "name": "Indacaterol", "description": "In the morning, powder filled capsules inhaled using a single dose dry powder inhaler (SDDPI).", "armGroupLabels": ["Ind 150 \u03bcg-Ind 600 \u03bcg-Placebo-Ind 300 \u03bcg-Salmeterol", "Ind 300 \u03bcg-Placebo-Ind 600 \u03bcg-Ind 150 \u03bcg-Salmeterol", "Ind 600 \u03bcg-Ind 300 \u03bcg-Ind 150 \u03bcg-Placebo-Salmeterol", "Placebo-Ind 150 \u03bcg-Ind 300 \u03bcg-Ind 600 \u03bcg-Salmeterol"], "otherNames": ["QAB149"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).", "armGroupLabels": ["Ind 150 \u03bcg-Ind 600 \u03bcg-Placebo-Ind 300 \u03bcg-Salmeterol", "Ind 300 \u03bcg-Placebo-Ind 600 \u03bcg-Ind 150 \u03bcg-Salmeterol", "Ind 600 \u03bcg-Ind 300 \u03bcg-Ind 150 \u03bcg-Placebo-Salmeterol", "Placebo-Ind 150 \u03bcg-Ind 300 \u03bcg-Ind 600 \u03bcg-Salmeterol"]}, {"type": "DRUG", "name": "Salmeterol", "description": "Salmeterol 100 \u03bcg total dose taken on Day 1. 50 \u03bcg in the morning and 50 \u03bcg twelve hours post initial dose inhaled via Diskus\u00ae, an inhalation device for Salmeterol.", "armGroupLabels": ["Ind 150 \u03bcg-Ind 600 \u03bcg-Placebo-Ind 300 \u03bcg-Salmeterol", "Ind 300 \u03bcg-Placebo-Ind 600 \u03bcg-Ind 150 \u03bcg-Salmeterol", "Ind 600 \u03bcg-Ind 300 \u03bcg-Ind 150 \u03bcg-Placebo-Salmeterol", "Placebo-Ind 150 \u03bcg-Ind 300 \u03bcg-Ind 600 \u03bcg-Salmeterol"], "otherNames": ["Serevent"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Time) Area Under the Curve (AUC) From 22 to 24 Hours Post-dose on Day 2", "description": "Spirometry was conducted according to internationally accepted standards. Standardized area under the curve (AUC22-24h) of FEV1 values taken at 22, 23 and 24 hours post dose, was calculated based on the trapezoidal rule. Analysis of Covariance was carried out with a mixed model that used (period) baseline, defined as the value of FEV1 measured prior to the first study drug intake in the period, as a covariate.", "timeFrame": "22, 23, and 24 hours post-dose on Day 2"}], "secondaryOutcomes": [{"measure": "Forced Expiratory Volume in 1 Second (FEV1) by Time Point From 5 Minutes to 12 Hours Post-dose on Day 1 and From 22 to 24 Hours Post-dose on Day 2", "description": "Spirometry was conducted according to internationally accepted standards. FEV1 by time point was calculated using a mixed model with (period) baseline, defined as the value measured prior to the first study drug intake in the period, as a covariate.", "timeFrame": "5, 15, and 30 minutes; and 1, 2, 4, 8, and 12 hours post-dose on Day 1; and 22, 23, and 24 hours post-dose on Day 2"}, {"measure": "Peak Forced Expiratory Volume in 1 Second (FEV1) From 5 Minutes to 4 Hours Post-dose on Day 1", "description": "Spirometry was conducted according to internationally accepted standards. Peak FEV1 is the maximum FEV1 recorded in the period between 5 minutes and 4 hours post dose. Analysis of Covariance was carried out with a mixed model that used (period) baseline, defined as the value of FEV1 measured prior to the first study drug intake in the period, as a covariate.", "timeFrame": "5 minutes to 4 hours post-dose on Day 1"}, {"measure": "Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Time) Area Under the Curve (AUC) From 5 Minutes Post-dose on Day 1 to 24 Hours Post-dose on Day 2", "description": "Spirometry was conducted according to internationally accepted standards. Standardized area under the curve (AUC0-24h) of FEV1 values taken at pre-dose to 24 hours post dose was calculated based on the trapezoidal rule. Analysis of Covariance was carried out with a mixed model that used (period) baseline, defined as the value of FEV1 measured prior to the first study drug intake in the period, as a covariate.", "timeFrame": "5 minutes to 12 hours post-dose on Day 1; and 22 to 24 hours post-dose on Day 2"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female Japanese asthmatic patients aged 18 to 75 years old.\n\nExclusion Criteria:\n\n* Patients who have been hospitalized or had emergency room treatment for an acute asthma attack in the 6 months prior to the first day of screening or during the screening period.\n* Patients who have used tobacco products within 6 months prior to the first day of screening or have a smoking history of greater than 10 pack years.\n* Patients with a history of malignancy with the exception of localized basal cell carcinoma of the skin.\n* Pregnant or nursing (lactating) women.\n* Patients who have had treatment with disallowed medications including investigational drug.\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals Japan", "affiliation": "Novartis Pharmaceuticals Japan", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Kasukabe", "country": "Japan", "geoPoint": {"lat": 35.98308, "lon": 139.74966}}, {"facility": "Novartis Investigator Site", "city": "Kishiwada", "country": "Japan", "geoPoint": {"lat": 34.46667, "lon": 135.36667}}, {"facility": "Novartis Investigative Site", "city": "Shimotsuga", "country": "Japan"}, {"facility": "Novartis Investigator Site", "city": "Suita", "country": "Japan", "geoPoint": {"lat": 34.76143, "lon": 135.51567}}, {"facility": "Novartis Investigative Site", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Novartis", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Novartis Investigator Site", "city": "Wakayama", "country": "Japan", "geoPoint": {"lat": 34.23333, "lon": 135.16667}}, {"facility": "Novartis Investigator Site", "city": "Yokohama", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A 14 day eligibility screening period insured all participants were stable on their permissible asthma treatment before proceeding onto core study drug treatment.", "groups": [{"id": "FG000", "title": "Placebo-Ind 150 \u03bcg-Ind 300 \u03bcg-Ind 600 \u03bcg-Salmeterol", "description": "In treatment period 1: patients received 2 placebo capsules; in treatment period 2: patients received 1 indacaterol (Ind) 150 \u03bcg capsule + 1 placebo capsule; in treatment period 3: patients received 1 indacaterol 300 \u03bcg capsule + 1 placebo capsule; and in treatment period 4: patients received 2 indacaterol 300 \u03bcg capsules. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 \u03bcg salmeterol (50 \u03bcg in the morning, 50 \u03bcg twelve hours post initial dose) inhaled via Diskus\u00ae, an inhalation device, on Day 1.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}, {"id": "FG001", "title": "Ind 150 \u03bcg-Ind 600 \u03bcg-Placebo-Ind 300 \u03bcg-Salmeterol", "description": "In treatment period 1: patients received 1 indacaterol (Ind) 150 \u03bcg capsule + 1 placebo capsule; in treatment period 2: patients received 2 indacaterol 300 \u03bcg capsules; in treatment period 3: patients received 2 placebo capsules; and in treatment period 4: patients received 1 indacaterol 300 \u03bcg capsule + 1 placebo capsule. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 \u03bcg salmeterol (50 \u03bcg in the morning, 50 \u03bcg twelve hours post initial dose) inhaled via Diskus\u00ae, an inhalation device, on Day 1.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}, {"id": "FG002", "title": "Ind 300 \u03bcg-Placebo-Ind 600 \u03bcg-Ind 150 \u03bcg-Salmeterol", "description": "In treatment period 1: patients received 1 indacaterol (Ind) 300 \u03bcg capsule + 1 placebo capsule; in treatment period 2: patients received 2 placebo capsules; in treatment period 3: patients received 2 indacaterol 300 \u03bcg capsules; and in treatment period 4: patients received 1 indacaterol 150 \u03bcg capsule + 1 placebo capsule. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 \u03bcg salmeterol (50 \u03bcg in the morning, 50 \u03bcg twelve hours post initial dose) inhaled via Diskus\u00ae, an inhalation, device on Day 1.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use t"}, {"id": "FG003", "title": "Ind 600 \u03bcg-Ind 300 \u03bcg-Ind150 \u03bcg-Placebo-Salmeterol", "description": "In treatment period 1: patients received 2 indacaterol (Ind) 300 \u03bcg capsules; in treatment period 2: patients received 1 indacaterol 300 \u03bcg capsule + 1 placebo capsule; in treatment period 3: patients received 1 indacaterol 150 \u03bcg capsule + 1 placebo capsule; and in treatment period 4: patients received 2 placebo capsules. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 \u03bcg salmeterol (50 \u03bcg in the morning, 50 \u03bcg twelve hours post initial dose) inhaled via Diskus\u00ae, an inhalation device, on Day 1.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use t"}], "periods": [{"title": "Core Treatment Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Core Treatment Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Core Treatment Period 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Core Treatment Period 4", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Open Label: Salmeterol", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Entire Study Population", "description": "The entire study population included all 4 treatment groups who received indacaterol 150 \u00b5g, 300 \u00b5g, and 600 \u00b5g and placebo via a single dose dry powder inhaler (SDDPI) in the 4 different sequences of the core phase. Two capsules of study medication were inhaled in the morning on Day 1 of each treatment period. Following the core phase patients continued to the Salmeterol open label phase. Salmeterol was inhaled via a Diskus inhalation device 50 \u00b5g in the morning and 50 \u00b5g 12 hours post initial dose on Day 1. Patients received each treatment only once.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "41"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "47.8", "spread": "14.90"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "21"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "20"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Time) Area Under the Curve (AUC) From 22 to 24 Hours Post-dose on Day 2", "description": "Spirometry was conducted according to internationally accepted standards. Standardized area under the curve (AUC22-24h) of FEV1 values taken at 22, 23 and 24 hours post dose, was calculated based on the trapezoidal rule. Analysis of Covariance was carried out with a mixed model that used (period) baseline, defined as the value of FEV1 measured prior to the first study drug intake in the period, as a covariate.", "populationDescription": "Modified intent-to-treat (modified ITT) population: All randomized patients who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "22, 23, and 24 hours post-dose on Day 2", "groups": [{"id": "OG000", "title": "Indacaterol 600 \u00b5g", "description": "Two capsules of indacaterol 300 \u00b5g were inhaled using a single dose dry powder inhaler (SDDPI) device in the morning on Day 1 of the treatment period. Indacaterol 600 \u00b5g was administered only once to each patient.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 300 \u00b5g", "description": "One capsule of indacaterol 300 \u00b5g and 1 placebo capsule were inhaled using a single dose dry powder inhaler (SDDPI) device in the morning on Day 1 of the treatment period. Indacaterol 300 \u00b5g was administered only once to each patient.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Indacaterol 150 \u00b5g", "description": "One capsule of indacaterol 150 \u00b5g and 1 placebo capsule were inhaled using a single dose dry powder inhaler (SDDPI) device in the morning on Day 1 of the treatment period. Indacaterol 150 \u00b5g was administered only once to each patient.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}, {"id": "OG003", "title": "Placebo", "description": "Two placebo capsules were inhaled using a single dose dry powder inhaler (SDDPI) device in the morning on Day 1 of the treatment period. Placebo was administered to each patient only once.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}, {"id": "OG004", "title": "Salmeterol 100 \u03bcg", "description": "Open label Salmeterol 100 \u03bcg total dose taken on Day 1. 50 \u03bcg in the morning and 50 \u03bcg twelve hours post initial dose inhaled via Diskus\u00ae, an inhalation device for Salmeterol.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "40"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "40"}, {"groupId": "OG004", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.31", "spread": "0.023"}, {"groupId": "OG001", "value": "2.28", "spread": "0.022"}, {"groupId": "OG002", "value": "2.24", "spread": "0.022"}, {"groupId": "OG003", "value": "2.06", "spread": "0.022"}, {"groupId": "OG004", "value": "2.23", "spread": "0.022"}]}]}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) by Time Point From 5 Minutes to 12 Hours Post-dose on Day 1 and From 22 to 24 Hours Post-dose on Day 2", "description": "Spirometry was conducted according to internationally accepted standards. FEV1 by time point was calculated using a mixed model with (period) baseline, defined as the value measured prior to the first study drug intake in the period, as a covariate.", "populationDescription": "Modified intent-to-treat (modified ITT) population: All randomized patients who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "5, 15, and 30 minutes; and 1, 2, 4, 8, and 12 hours post-dose on Day 1; and 22, 23, and 24 hours post-dose on Day 2", "groups": [{"id": "OG000", "title": "Indacaterol 600 \u00b5g", "description": "Two capsules of indacaterol 300 \u00b5g were inhaled using a single dose dry powder inhaler (SDDPI) device in the morning on Day 1 of the treatment period. Indacaterol 600 \u00b5g was administered only once to each patient.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 300 \u00b5g", "description": "One capsule of indacaterol 300 \u00b5g and 1 placebo capsule were inhaled using a single dose dry powder inhaler (SDDPI) device in the morning on Day 1 of the treatment period. Indacaterol 300 \u00b5g was administered only once to each patient.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Indacaterol 150 \u00b5g", "description": "One capsule of indacaterol 150 \u00b5g and 1 placebo capsule were inhaled using a single dose dry powder inhaler (SDDPI) device in the morning on Day 1 of the treatment period. Indacaterol 150 \u00b5g was administered only once to each patient.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}, {"id": "OG003", "title": "Placebo", "description": "Two placebo capsules were inhaled using a single dose dry powder inhaler (SDDPI) device in the morning on Day 1 of the treatment period. Placebo was administered to each patient only once.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}, {"id": "OG004", "title": "Salmeterol 100 \u03bcg", "description": "Open label Salmeterol 100 \u03bcg total dose taken on Day 1. 50 \u03bcg in the morning and 50 \u03bcg twelve hours post initial dose inhaled via Diskus\u00ae, an inhalation device for Salmeterol.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "40"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "40"}, {"groupId": "OG004", "value": "39"}]}], "classes": [{"title": "5 minutes", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.25", "lowerLimit": "2.22", "upperLimit": "2.27"}, {"groupId": "OG001", "value": "2.20", "lowerLimit": "2.18", "upperLimit": "2.23"}, {"groupId": "OG002", "value": "2.19", "lowerLimit": "2.16", "upperLimit": "2.22"}, {"groupId": "OG003", "value": "2.04", "lowerLimit": "2.01", "upperLimit": "2.07"}, {"groupId": "OG004", "value": "2.13", "lowerLimit": "2.10", "upperLimit": "2.15"}]}]}, {"title": "15 minutes", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.33", "lowerLimit": "2.30", "upperLimit": "2.36"}, {"groupId": "OG001", "value": "2.28", "lowerLimit": "2.25", "upperLimit": "2.32"}, {"groupId": "OG002", "value": "2.27", "lowerLimit": "2.24", "upperLimit": "2.30"}, {"groupId": "OG003", "value": "2.05", "lowerLimit": "2.02", "upperLimit": "2.08"}, {"groupId": "OG004", "value": "2.19", "lowerLimit": "2.16", "upperLimit": "2.22"}]}]}, {"title": "30 minutes", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.37", "lowerLimit": "2.34", "upperLimit": "2.41"}, {"groupId": "OG001", "value": "2.33", "lowerLimit": "2.30", "upperLimit": "2.37"}, {"groupId": "OG002", "value": "2.30", "lowerLimit": "2.27", "upperLimit": "2.34"}, {"groupId": "OG003", "value": "2.07", "lowerLimit": "2.03", "upperLimit": "2.10"}, {"groupId": "OG004", "value": "2.24", "lowerLimit": "2.21", "upperLimit": "2.27"}]}]}, {"title": "1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.41", "lowerLimit": "2.38", "upperLimit": "2.45"}, {"groupId": "OG001", "value": "2.35", "lowerLimit": "2.32", "upperLimit": "2.38"}, {"groupId": "OG002", "value": "2.32", "lowerLimit": "2.29", "upperLimit": "2.35"}, {"groupId": "OG003", "value": "2.09", "lowerLimit": "2.06", "upperLimit": "2.12"}, {"groupId": "OG004", "value": "2.29", "lowerLimit": "2.25", "upperLimit": "2.32"}]}]}, {"title": "2 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.45", "lowerLimit": "2.41", "upperLimit": "2.48"}, {"groupId": "OG001", "value": "2.39", "lowerLimit": "2.35", "upperLimit": "2.43"}, {"groupId": "OG002", "value": "2.38", "lowerLimit": "2.34", "upperLimit": "2.42"}, {"groupId": "OG003", "value": "2.13", "lowerLimit": "2.09", "upperLimit": "2.16"}, {"groupId": "OG004", "value": "2.34", "lowerLimit": "2.30", "upperLimit": "2.37"}]}]}, {"title": "4 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.42", "lowerLimit": "2.38", "upperLimit": "2.47"}, {"groupId": "OG001", "value": "2.39", "lowerLimit": "2.35", "upperLimit": "2.43"}, {"groupId": "OG002", "value": "2.35", "lowerLimit": "2.31", "upperLimit": "2.39"}, {"groupId": "OG003", "value": "2.10", "lowerLimit": "2.06", "upperLimit": "2.14"}, {"groupId": "OG004", "value": "2.34", "lowerLimit": "2.30", "upperLimit": "2.38"}]}]}, {"title": "8 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.37", "lowerLimit": "2.33", "upperLimit": "2.41"}, {"groupId": "OG001", "value": "2.35", "lowerLimit": "2.31", "upperLimit": "2.38"}, {"groupId": "OG002", "value": "2.28", "lowerLimit": "2.24", "upperLimit": "2.31"}, {"groupId": "OG003", "value": "2.06", "lowerLimit": "2.02", "upperLimit": "2.09"}, {"groupId": "OG004", "value": "2.25", "lowerLimit": "2.21", "upperLimit": "2.29"}]}]}, {"title": "12 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.33", "lowerLimit": "2.28", "upperLimit": "2.37"}, {"groupId": "OG001", "value": "2.30", "lowerLimit": "2.26", "upperLimit": "2.34"}, {"groupId": "OG002", "value": "2.24", "lowerLimit": "2.20", "upperLimit": "2.28"}, {"groupId": "OG003", "value": "2.00", "lowerLimit": "1.96", "upperLimit": "2.05"}, {"groupId": "OG004", "value": "2.20", "lowerLimit": "2.16", "upperLimit": "2.24"}]}]}, {"title": "22 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.30", "lowerLimit": "2.26", "upperLimit": "2.34"}, {"groupId": "OG001", "value": "2.25", "lowerLimit": "2.21", "upperLimit": "2.29"}, {"groupId": "OG002", "value": "2.20", "lowerLimit": "2.16", "upperLimit": "2.24"}, {"groupId": "OG003", "value": "2.01", "lowerLimit": "1.97", "upperLimit": "2.05"}, {"groupId": "OG004", "value": "2.18", "lowerLimit": "2.14", "upperLimit": "2.22"}]}]}, {"title": "23 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.32", "lowerLimit": "2.28", "upperLimit": "2.36"}, {"groupId": "OG001", "value": "2.28", "lowerLimit": "2.25", "upperLimit": "2.32"}, {"groupId": "OG002", "value": "2.25", "lowerLimit": "2.21", "upperLimit": "2.29"}, {"groupId": "OG003", "value": "2.06", "lowerLimit": "2.02", "upperLimit": "2.10"}, {"groupId": "OG004", "value": "2.23", "lowerLimit": "2.20", "upperLimit": "2.27"}]}]}, {"title": "24 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.32", "lowerLimit": "2.28", "upperLimit": "2.35"}, {"groupId": "OG001", "value": "2.29", "lowerLimit": "2.25", "upperLimit": "2.33"}, {"groupId": "OG002", "value": "2.26", "lowerLimit": "2.22", "upperLimit": "2.30"}, {"groupId": "OG003", "value": "2.09", "lowerLimit": "2.06", "upperLimit": "2.13"}, {"groupId": "OG004", "value": "2.27", "lowerLimit": "2.23", "upperLimit": "2.31"}]}]}]}, {"type": "SECONDARY", "title": "Peak Forced Expiratory Volume in 1 Second (FEV1) From 5 Minutes to 4 Hours Post-dose on Day 1", "description": "Spirometry was conducted according to internationally accepted standards. Peak FEV1 is the maximum FEV1 recorded in the period between 5 minutes and 4 hours post dose. Analysis of Covariance was carried out with a mixed model that used (period) baseline, defined as the value of FEV1 measured prior to the first study drug intake in the period, as a covariate.", "populationDescription": "Modified intent-to-treat (modified ITT) population: All randomized patients who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "5 minutes to 4 hours post-dose on Day 1", "groups": [{"id": "OG000", "title": "Indacaterol 600 \u00b5g", "description": "Two capsules of indacaterol 300 \u00b5g were inhaled using a single dose dry powder inhaler (SDDPI) device in the morning on Day 1 of the treatment period. Indacaterol 600 \u00b5g was administered only once to each patient.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 300 \u00b5g", "description": "One capsule of indacaterol 300 \u00b5g and 1 placebo capsule were inhaled using a single dose dry powder inhaler (SDDPI) device in the morning on Day 1 of the treatment period. Indacaterol 300 \u00b5g was administered only once to each patient.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Indacaterol 150 \u00b5g", "description": "One capsule of indacaterol 150 \u00b5g and 1 placebo capsule were inhaled using a single dose dry powder inhaler (SDDPI) device in the morning on Day 1 of the treatment period. Indacaterol 150 \u00b5g was administered only once to each patient.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}, {"id": "OG003", "title": "Placebo", "description": "Two placebo capsules were inhaled using a single dose dry powder inhaler (SDDPI) device in the morning on Day 1 of the treatment period. Placebo was administered to each patient only once.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}, {"id": "OG004", "title": "Salmeterol 100 \u03bcg", "description": "Open label Salmeterol 100 \u03bcg total dose taken on Day 1. 50 \u03bcg in the morning and 50 \u03bcg twelve hours post initial dose inhaled via Diskus\u00ae, an inhalation device for Salmeterol.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "40"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "40"}, {"groupId": "OG004", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.49", "spread": "0.018"}, {"groupId": "OG001", "value": "2.44", "spread": "0.018"}, {"groupId": "OG002", "value": "2.41", "spread": "0.018"}, {"groupId": "OG003", "value": "2.19", "spread": "0.18"}, {"groupId": "OG004", "value": "2.39", "spread": "0.018"}]}]}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Time) Area Under the Curve (AUC) From 5 Minutes Post-dose on Day 1 to 24 Hours Post-dose on Day 2", "description": "Spirometry was conducted according to internationally accepted standards. Standardized area under the curve (AUC0-24h) of FEV1 values taken at pre-dose to 24 hours post dose was calculated based on the trapezoidal rule. Analysis of Covariance was carried out with a mixed model that used (period) baseline, defined as the value of FEV1 measured prior to the first study drug intake in the period, as a covariate.", "populationDescription": "Modified intent-to-treat (modified ITT) population: All randomized patients who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "5 minutes to 12 hours post-dose on Day 1; and 22 to 24 hours post-dose on Day 2", "groups": [{"id": "OG000", "title": "Indacaterol 600 \u00b5g", "description": "Two capsules of indacaterol 300 \u00b5g were inhaled using a single dose dry powder inhaler (SDDPI) device in the morning on Day 1 of the treatment period. Indacaterol 600 \u00b5g was administered only once to each patient.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 300 \u00b5g", "description": "One capsule of indacaterol 300 \u00b5g and 1 placebo capsule were inhaled using a single dose dry powder inhaler (SDDPI) device in the morning on Day 1 of the treatment period. Indacaterol 300 \u00b5g was administered only once to each patient.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Indacaterol 150 \u00b5g", "description": "One capsule of indacaterol 150 \u00b5g and 1 placebo capsule were inhaled using a single dose dry powder inhaler (SDDPI) device in the morning on Day 1 of the treatment period. Indacaterol 150 \u00b5g was administered only once to each patient.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}, {"id": "OG003", "title": "Placebo", "description": "Two placebo capsules were inhaled using a single dose dry powder inhaler (SDDPI) device in the morning on Day 1 of the treatment period. Placebo was administered to each patient only once.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}, {"id": "OG004", "title": "Salmeterol 100 \u03bcg", "description": "Open label Salmeterol 100 \u03bcg total dose taken on Day 1. 50 \u03bcg in the morning and 50 \u03bcg twelve hours post initial dose inhaled via Diskus\u00ae, an inhalation device for Salmeterol.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "40"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "40"}, {"groupId": "OG004", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.35", "spread": "0.022"}, {"groupId": "OG001", "value": "2.31", "spread": "0.021"}, {"groupId": "OG002", "value": "2.26", "spread": "0.021"}, {"groupId": "OG003", "value": "2.04", "spread": "0.021"}, {"groupId": "OG004", "value": "2.24", "spread": "0.021"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "Safety Population included all participants who received at least one dose of study drug.", "eventGroups": [{"id": "EG000", "title": "Indacaterol 150 \u03bcg", "description": "1 Indacaterol 150 \u03bcg capsule + 1 Placebo capsule were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of the Indacaterol 150 \u03bcg treatment period.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 40, "otherNumAffected": 14, "otherNumAtRisk": 40}, {"id": "EG001", "title": "Indacaterol 300 \u03bcg", "description": "1 Indacaterol 300 \u03bcg capsules + 1 Placebo capsule were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of the Indacaterol 300 \u03bcg treatment period.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 40, "otherNumAffected": 14, "otherNumAtRisk": 40}, {"id": "EG002", "title": "Indacaterol 600 \u03bcg", "description": "2 Indacaterol 300 \u03bcg capsules were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of the Indacaterol 600 \u03bcg treatment period.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 39, "otherNumAffected": 14, "otherNumAtRisk": 39}, {"id": "EG003", "title": "Placebo", "description": "2 Placebo capsules were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of the Placebo treatment period.\n\nDaily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 40, "otherNumAffected": 6, "otherNumAtRisk": 40}, {"id": "EG004", "title": "Salmeterol 100 \u03bcg", "description": "Open label Salmeterol 100 \u03bcg total dose taken on Day 1. 50 \u03bcg in the morning and 50 \u03bcg twelve hours post initial dose inhaled via Diskus\u00ae, an inhalation device for Salmeterol. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 39, "otherNumAffected": 1, "otherNumAtRisk": 39}], "otherEvents": [{"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 40}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 39}]}, {"term": "COUGH", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 40}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 14, "numAtRisk": 39}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 40}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 39}]}, {"term": "OBSTRUCTIVE AIRWAYS DISORDER", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 39}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862 778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068299", "term": "Salmeterol Xinafoate"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "relevance": "LOW"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}